文献速递血脂与心血管预防

贝派地酸在高胆固醇血症III期随机临床试验中对致动脉粥样硬化血脂水平的影响

Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia.
PubMed 文献 · JAMA Cardiol · 2020-01-01

该汇总分析纳入4项双盲安慰剂对照III期随机试验,共3623例高胆固醇血症患者,随机2:1接受贝派地酸180 mg每日一次或安慰剂治疗12至52周。在第12周,贝派地酸组LDL-C较基线降幅显著大于安慰剂组,且长期随访中降幅持续,安全谱可接受,常见不良事件包括血尿酸升高、痛风、肾小球滤过率下降和肝酶升高。

要点

  • 贝派地酸180 mg每日一次可显著降低高胆固醇血症患者的LDL-C水平。
  • 降LDL-C效应在动脉粥样硬化性心血管疾病/杂合子家族性高胆固醇血症和他汀不耐受患者中均持续。
  • 贝派地酸可作为非他汀类附加或替代治疗,但需关注尿酸、痛风和肝酶等不良事件。

核心结论

  • 在最大耐受他汀基础上加用贝派地酸,或用于他汀不耐受患者,可显著降低LDL-C水平,安全谱可接受。

研究设计与样本

  • 汇总4项双盲、安慰剂对照III期随机临床试验(2016–2018年),患者来自北美和欧洲。
  • 共3623例高胆固醇血症患者,随机2:1接受贝派地酸180 mg(n=2425)或安慰剂(n=1198)每日一次,治疗12至52周。

主要发现

  • 在动脉粥样硬化性心血管疾病或杂合子家族性高胆固醇血症或两者兼有且接受他汀治疗的患者中,第12周LDL-C较基线变化:贝派地酸组-16.0%,安慰剂组1.8%,差异-17.8%(95% CI -19.5%至-16.0%,P < .001)。
  • 在他汀不耐受患者中,第12周LDL-C较基线变化:贝派地酸组-23.0%,安慰剂组1.5%,差异-24.5%(95% CI -27.8%至-21.1%,P < .001)。
  • 长期随访中LDL-C降幅持续:动脉粥样硬化性心血管疾病或杂合子家族性高胆固醇血症或两者兼有且接受最大耐受他汀的患者第52周差异-12.7%;他汀不耐受患者第24周差异-22.2%。
  • 贝派地酸组非高密度脂蛋白胆固醇、总胆固醇、载脂蛋白B和高敏C反应蛋白的降幅均大于安慰剂组。
  • 贝派地酸组较安慰剂组更常见的不良事件包括血尿酸升高(2.1% vs 0.5%)、痛风(1.4% vs 0.4%)、肾小球滤过率下降(0.7% vs <0.1%)和肝酶升高(2.8% vs 1.3%)。

临床怎么用

  • 对于接受最大耐受他汀但LDL-C仍不达标的高胆固醇血症患者,可考虑加用贝派地酸。
  • 对于他汀不耐受的高胆固醇血症患者,贝派地酸可作为他汀替代选择。
  • 使用贝派地酸时应监测血尿酸、痛风症状、肾功能和肝酶。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Additional lipid-lowering therapy options are needed for patients who cannot achieve sufficient decreases in low-density lipoprotein cholesterol (LDL-C) levels using statins alone or for those who are statin intolerant. OBJECTIVE: To conduct a pooled analysis of phase 3 randomized clinical trials of bempedoic acid vs placebo. DESIGN, SETTING, AND PARTICIPANTS: This analysis pooled data from 4 double-blind, placebo-controlled randomized clinical trials conducted from 2016 to 2018. Patients were enrolled in North America and Europe. Eligibility criteria included hypercholesterolemia while receiving stable lipid-lowering therapy and high cardiovascular risk or hypercholesterolemia and statin intolerance. INTERVENTIONS: Patients were randomized 2:1 to bempedoic acid, 180 mg (n = 2425), or placebo (n = 1198) once daily for 12 to 52 weeks. MAIN OUTCOMES AND MEASURES: Primary efficacy end point was percentage change from baseline in LDL-C level at week 12 in the intention-to-treat population. Patients were parsed into 2 groups according to enrollment criteria: (1) patients with hypercholesterolemia and atherosclerotic cardiovascular disease (ASCVD) or with heterozygous familial hypercholesterolemia (HeFH) or with both and receiving statins and (2) patients with hypercholesterolemia who were statin intolerant receiving maximally tolerated statins. RESULTS: In this analysis of 3623 patients, the overall mean (SD) patient age was 65.5 (9.2) years (similar in both pools). Among patients with ASCVD or HeFH or both, the mean (SD) baseline LDL-C level was 107.6 (32.7) mg/dL. At week 12, the LDL-C level percentage change from baseline was -16.0% with bempedoic acid vs 1.8% with placebo (difference, -17.8%; 95% CI, -19.5% to -16.0%; P < .001). Patients with statin intolerance had a mean (SD) baseline LDL-C level of 144.4 (38.8) mg/dL. The percentage changes in LDL-C levels at week 12 were -23.0% in the bempedoic acid group and 1.5% in the placebo group (difference, -24.5%; 95% CI, -27.8% to -21.1%; P < .001). The decrease in LDL-C levels with bempedoic acid was sustained during long-term follow-up in both pools (patients with ASCVD or HeFH or both receiving a maximally tolerated statin, difference of -12.7% at week 52; patients with statin intolerance, difference of -22.2% at week 24). Decreases in non-high-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, and high-sensitivity C-reactive protein levels were greater with bempedoic acid vs placebo. Treatment-emergent adverse events associated more frequently with bempedoic acid than with placebo included increased blood uric acid level (2.1% vs 0.5%), gout (1.4% vs 0.4%), decreased glomerular filtration rate (0.7% vs <0.1%), and increased levels of hepatic enzymes (2.8% vs 1.3%). CONCLUSIONS AND RELEVANCE: Bempedoic acid added to maximally tolerated statins, including moderate- or high-intensity statins or no background statin, was associated with decreased LDL-C levels vs placebo in patients with hypercholesterolemia with an acceptable safety profile. As a nonstatin adjunct or statin alternative, bempedoic acid has potential for use in a broad spectrum of patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT02666664, NCT02991118, NCT03001076, and NCT02988115.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Banach M, Duell PB, Gotto AM, et al. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. JAMA Cardiol. 2020. PMID: 32609313. doi:10.1001/jamacardio.2020.2314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。